NICE Single Technology Appraisal Guidance No 213 – Aripiprazole
for the treatment of schizophrenia in people aged 15-17
This NICE Guidance was
published, 26 January 2011. The web reference for the
appraisal and other related documents is: www.nice.org.uk/TA213
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHS Scotland.
2. NHS Boards should continue to adhere to the
SMC advice.
The Scottish Medicines Consortium (SMC)
published a Statement of Advice (630/10) on this medication for
this indication in August 2010 following an abbreviated submission.
This stated that:
Aripiprazole tablets, orodispersible tablets and
oral solution (Abilify®) are accepted for restricted use within NHS
Scotland for the treatment of schizophrenia in adolescents 15 years
and older. Use is restricted to initiation and management under the
supervision of a child/adolescent psychiatrist.
Read the advice of the Scottish Medicines Consortum
3. There is a material difference between the
recommendations of the NICE STA and the SMC. NICE recommend
aripiprazole as an option for those who are intolerant of
risperidone, or for whom risperidone is contraindicated, or whose
schizophrenia has not been adequately controlled with risperidone.
Note that in this case the SMC advice was based on an abbreviated
submission from the manufacturer.
If you need further assistance, please contact Eleanor Brownlee
in the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net).
Published Date: 26 January 2011
